CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...